Accession Number:

ADA361863

Title:

Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin.

Descriptive Note:

Annual rept. 23 Sep 97-22 Sep 98

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

• Perez-Soler, Roman

Report Date:

1998-10-01

Pagination or Media Count:

7.0

Abstract:

Nine patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 14 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50 of patients. No antitumor responses were seen.

Descriptors:

• *CARCINOGENS
• *MAMMARY GLANDS
• *DRUG TOLERANCE
• *METASTASIS
• *BREAST CANCER
• TOXICITY
• NEOPLASMS
• DOSAGE
• LEVEL(QUANTITY)

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE